At ASCO 2026, Lunit will present precision patient stratification and biomarker-driven oncology research through AI-powered HER2/IHC biomarker quantification and spatial tumor microenvironment ...
Clinical utility of circulating tumor RNA (ctRNA) in a combined circulating tumor DNA (ctDNA) and ctRNA next-generation sequencing (NGS) pan-cancer liquid biopsy assay. Preliminary results from a ...
The tumor microenvironment is a complex mix of cancer cells, immune cells, and other components that all play a part in tumor progression, metastasis, and therapy responses. Understanding the highly ...
Vietnam Investment Review on MSN
Lunit presents AI powered cancer biomarker research at ASCO 2026
SEOUL, South Korea, May 22, 2026 /PRNewswire/ -- Lunit, a leading provider of AI for cancer diagnostics and precision oncology, today announces that five studies featuring its AI biomarker platforms ...
In-hospital outcomes of acute pulmonary embolism admissions in individuals with genitourinary cancers: Insights from a national population study in the United States. This is an ASCO Meeting Abstract ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results